KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Cash & Equivalents: 2018-2025

Historic Cash & Equivalents for BioNTech SE (BNTX) over the last 7 years, with Sep 2025 value amounting to $11.8 billion.

  • BioNTech SE's Cash & Equivalents rose 11.63% to $11.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 billion, marking a year-over-year increase of 11.63%. This contributed to the annual value of $10.4 billion for FY2024, which is 16.88% down from last year.
  • BioNTech SE's Cash & Equivalents amounted to $11.8 billion in Q3 2025, which was up 1.50% from $11.6 billion recorded in Q2 2025.
  • BioNTech SE's Cash & Equivalents' 5-year high stood at $15.4 billion during Q2 2023, with a 5-year trough of $432.8 million in Q3 2021.
  • For the 3-year period, BioNTech SE's Cash & Equivalents averaged around $12.0 billion, with its median value being $11.6 billion (2025).
  • In the last 5 years, BioNTech SE's Cash & Equivalents tumbled by 35.34% in 2021 and then soared by 3,027.27% in 2022.
  • Over the past 5 years, BioNTech SE's Cash & Equivalents (Quarterly) stood at $1.9 billion in 2021, then soared by 631.05% to $14.2 billion in 2022, then fell by 11.35% to $12.5 billion in 2023, then decreased by 16.88% to $10.4 billion in 2024, then grew by 11.63% to $11.8 billion in 2025.
  • Its last three reported values are $11.8 billion in Q3 2025, $11.6 billion for Q2 2025, and $10.7 billion during Q1 2025.